Supplementary Material: HCC Patient Outcomes with Triple Therapy from CLEAP Database

627 patient records from a multicenter retrospective cohort study evaluating the efficacy and safety of triple therapy for hepatocellular carcinoma. The data originates from the CLEAP database covering the period from 2019 to 2023. It includes endpoints such as overall survival, progression-free survival, treatment response, and adverse events.

Use Cases

• Risk stratification modeling based on the Charlson Comorbidity Index.
• Predicting treatment-related adverse events using the age-adjusted Charlson Comorbidity Index.
• Analyzing survival outcomes (OS and PFS) for patients receiving triple therapy.
• Comparing efficacy and safety metrics between elderly and younger patient cohorts.

Strengths

• Includes 627 patient records from a multicenter study.
• Covers a defined time range from 2019 to 2023.
• Contains primary endpoints (OS, PFS) and secondary endpoints (treatment response, adverse events).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect temporal and source bias inherent to the CLEAP database.

Provenance

Source

CLEAP database.

Collection Method

Multicenter retrospective cohort study.

Time Range

2019–2023.

Freshness

Last updated 2026-04-21 05:55:27; freshness should be verified.